Developing a new nanoparticle-based treatment for non-small cell lung cancer
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment
This study is testing a new treatment called ARAC-02 for people with non-small cell lung cancer, using tiny particles to deliver a mix of medicines directly to the tumors to help the immune system fight the cancer better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pdx Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Portland, UNITED STATES) |
| Project ID | NIH-10922377 on NIH RePORTER |
What this research studies
This research focuses on creating an innovative immunotherapy called ARAC-02 for patients with non-small cell lung cancer (NSCLC). It utilizes a unique nanoparticle platform to deliver multiple therapeutic agents directly to tumors, enhancing the immune response against cancer cells. The approach combines a specific siRNA to target cancer cell death, an antibody to block immune checkpoints, and an immune stimulant to improve antigen presentation. This multi-faceted strategy aims to improve treatment outcomes for NSCLC patients who currently have limited options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer who have not responded adequately to existing therapies.
Not a fit: Patients with other types of cancer or those who have already received extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment efficacy for patients with non-small cell lung cancer.
How similar studies have performed: Previous research on nanoparticle-based immunotherapies has shown promising results, indicating potential for success with this novel approach.
Where this research is happening
Portland, UNITED STATES
- Pdx Pharmaceuticals, INC. — Portland, United States (Active)
Researchers
- Principal investigator: Ngamcherdtrakul, Worapol — Pdx Pharmaceuticals, INC.
- Study coordinator: Ngamcherdtrakul, Worapol
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.